Subcutaneous · GLP-1 / GIP dual
HDM1005
10 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
10
Active
8
Recruiting
5
Completed
2
Sites
6
Countries
1
Endpoints
75
Composite endpoints
1
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
4
Phase 2
3
Phase 3
3
Trials by status
Not yet recruiting
3
Recruiting
5
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
24
Weight & body composition
19
Glycemic / diabetes
13
Cardiometabolic biomarkers
10
Other (unclassified)
9
Most-measured metrics
Top 20 metrics across this asset's endpoints
Body weight, absolute change (kg)Weight
4
HbA1c, changeGlycemic
4
Diastolic BP, changeBiomarker
2
Systolic BP, changeBiomarker
2
Body weight, % changeWeight
2
Waist circumference, changeWeight
2
BMI, changeWeight
2
Fasting glucose, changeGlycemic
2
Immunogenicity (ADA)Safety/PK
1
Treatment-emergent AEs (any)Safety/PK
1
≥15% weight-loss respondersWeight
1
HbA1c <7.0% achievementGlycemic
1
HbA1c <6.5% achievementGlycemic
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
10 of 10